Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial

Autor: Steven R. Sarkisian, Robert E. Ang, Andy M. Lee, John P. Berdahl, Sebastian B. Heersink, James H. Burden, Long V. Doan, Kerry G. Stephens, David Applegate, Angela C. Kothe, Dale W. Usner, L. Jay Katz, Tomas Navratil
Jazyk: angličtina
Rok vydání: 2024
Předmět:
Zdroj: Ophthalmology and Therapy, Vol 13, Iss 4, Pp 995-1014 (2024)
Druh dokumentu: article
ISSN: 2193-8245
2193-6528
DOI: 10.1007/s40123-024-00898-y
Popis: Abstract Introduction This prospective, multicenter, randomized, double-masked pivotal phase 3 trial evaluated the efficacy and safety of the travoprost intracameral SE-implant (slow-eluting implant, the intended commercial product) and FE-implant (fast-eluting implant, included primarily for masking purposes) compared to twice-daily (BID) timolol ophthalmic solution, 0.5% in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods The trial enrolled adult patients with OAG or OHT with an unmedicated mean diurnal intraocular pressure (IOP) of ≥ 21 and unmedicated IOP ≤ 36 mmHg at each diurnal timepoint (8 a.m., 10 a.m., and 4 p.m.) at baseline. The eligible eye of each patient was administered an SE-implant, an FE-implant or had a sham administration procedure. Patients who received an implant were provided placebo eye drops to be administered BID and patients who had the sham procedure were provided timolol eye drops to be administered BID. The primary efficacy endpoint, for which the study was powered, was mean change from baseline IOP at 8 a.m. and 10 a.m. at day 10, week 6, and month 3. Non-inferiority was achieved if the upper 95% confidence interval (CI) on the difference in IOP change from baseline (implant minus timolol) was
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje